Jefferies Downgrades Supernus Pharmaceuticals (SUPN) to Hold
Tweet
Share
E-mailGet Alerts SUPN Hot Sheet
Price: $49.03 --0%
Rating Summary:
9 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 8 | New: 13
Rating Summary:
9 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 8 | New: 13
Join SI Premium – FREE
Jefferies analyst David Steinberg downgraded Supernus Pharmaceuticals (NASDAQ: SUPN) from Buy to Hold with a price target of $23.00 (from $46.00).
For an analyst ratings summary and ratings history on Supernus Pharmaceuticals click here. For more ratings news on Supernus Pharmaceuticals click here.
Shares of Supernus Pharmaceuticals closed at $29.13 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Home Depot (HD) PT Lowered to $420 at UBS, Buy Rating Maintained on Growth Potential
- Coloplast A/S (COLOB:DC) (CLPBY) PT Raised to DKK455 at Bernstein SocGen Group
- Jefferies Downgrades Pediatrix Medical Group (MD) to Hold
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
